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Available online 24 September 2016Treatment of acetaminophen (APAP) in overdose can cause a potentially serious and fatal liver injury.MicroRNA-
155 (miR-155), amultifunctionalmicroRNA, is known tomediate inﬂammatory responses via regulating various
target genes. In this study, we aimed to study the role of miR-155 in APAP-induced liver injury, using miR-
155−/−mice and miR-155 in vivo intervention.We noted that miR-155 expression was signiﬁcantly increased
in liver and blood after APAP treatment. Knockout of miR-155 deteriorated APAP-induced liver damage, with the
elevated serum levels of AST andALT. The levels of various inﬂammatorymediators, such as TNF-α and IL-6,were
markedly augmented in livers in the absence ofmiR-155. Moreover,miR-155 deﬁciency aberrantly activated NF-
kappa-B signaling via enhancing p65 and IKKε expression. Finally, in vivo administration of miR-155 agomir at-
tenuated APAP-induced liver damage, reduced the serum levels of AST and ALT, and dampened theNF-kB signal-
ing. In conclusion, our data demonstrated thatmiR-155 protects themice against APAP-induced liver damage via
mediating NF-KB signaling pathway, suggesting thatmiR-155might be a potential pharmaceutic target for treat-
ment of APAP-induced liver inﬂammation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inﬂammation1. Introduction
The liver in human body undertakes multiple tasks including detox-
iﬁcation, excretion of waste productions, nutrient take up and storage,
total energy metabolism, and secretion of important serum proteins
[1]. The speciﬁc functions make the liver a highly vulnerable organ to
toxic injury, which may trigger hepatic inﬂammation and the subse-
quent ﬁbrosis and end-stage tissue damage. Among all the hepatotoxic
chemical-induced injuries, acetaminophen (APAP) overdose is regarded
as themost common cause of acute liver failure in thewestern countries
[2]. Although approved for clinic use in the 1950s, it was not until the
1970s when the hepatotoxicity of APAP was widely recognized [3,4]. It
is once reported that more than 50% of all acute liver failure cases in
the United States implicate APAP poisoning, mostly due to the uninten-
tional overdose caused by consumption of multiple drugs containing
APAP [5,6].
The mechanism underlying APAP hepatotoxicity has been investi-
gated wildly. Although some of the mechanistic details remain elusive,
it is well known that APAP molecules enter the liver through its blood
ﬂow and cause cell necrosis of lobular areas, leading to the release ofiversity, 2000 Jiangyue Road,
. This is an open access article undercellular pro-inﬂammatorymediators, inﬁltration of polymorphonuclear
leukocyte and macrophage into the liver [7,8]. The secretion of pro-in-
ﬂammatory cytokines including tumor necrosis factor (TNF)-α, CCL-2
interleukin (IL)-1β and IL-6 has been reported to play crucial roles in
mediating inﬂammatory cell activation [9–11]. Therefore, a better un-
derstanding of the inﬂammatory responses induced by APAP overdose
may facilitate development of more effective therapeutic strategies for
treatment of APAP-induced liver toxicity.
MicroRNA (miRNA), a short and conserved noncoding RNA, controls
gene expression at a post-transcriptional level. A growing body of stud-
ies involving miRNA has advanced our understanding of the roles of
miRNA in the pathogenesis of molecular mechanisms of various liver
diseases [12–16]. Among other miRNAs, miR-155 is a pleotropic regula-
tor ofmediatingmultiple immune responses [17,18]. For example, in re-
sponse to innate stimulus, miR-155 is markedly upregulated in
macrophage [19]. During moDC maturation, miR-155 is highly induced
and inhibits interleukin-1 signaling pathway via targeting TAB2 [20]. A
recent study revealed a pro-inﬂammatory effect of miR-155 in alcoholic
liver disease (ALD) [21]. However, little is known about the role of miR-
155 in APAP-induced liver toxicity.
In this study, we found thatmiR-155 expressionwas signiﬁcantly in-
creased after APAP treatment. Knockout of miR-155 aggravates APAP-
induced liver damage, with the elevated serum levels of ASL and ALT.
The expression of various pro-inﬂammatory mediators, such as TNF-α
and IL-6 was markedly increased by the loss of miR-155. Furthermore,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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NF-kappa-B signaling via enhancing p65 and IKKε expression. Lucifer-
ase reporter experiments revealed that IKKε is a direct target of miR-
155. Finally, in vivo administration of miR-155 agomir attenuates
APAP-induced liver damage and inﬂammation.
2. Methods
2.1. Mice
Wild type C57BL/6J (B6) and B6.Cg-Mir155tm1.1Rsky/J mice were
purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). All
animals were propagated and housed in a speciﬁc-pathogen-free barri-
er facility, with 12 h light/dark cycle and allowed free access to food and
water. 8–10-week-oldmalemice, with the averageweight of 24 to 26 g,
were used for experiments. All experimental protocols involving ani-
mals were approved by the Animal Studies Committee of Shanghai
Renji Hospital.
2.2. APAP-induced liver injury
APAP (Sigma Chemical Co, St. Louis, MO) was prepared freshly by
dissolving the compound in pre-warmed phosphate buffered saline
(PBS, pH 7.4) before injection. Overnight fasted mice were either
given APAP (n = 10) at a dose of 300 mg/kg body weight or saline
(n = 10) by intraperitoneal (i.p.) injection. For miR-155 intervention
assay, mice were injected (i.v.) negative control (NC) agomir or miR-Fig. 1. Deteriorated APAP-induced liver injury by miR-155 deﬁciency. (A) The expression of m
sections of APAP-treated miR-155−/− and wild type (WT) livers. Magniﬁcation: 200×. (C) P
5–6 mice per group. Data shown were representative of three independent experiments. Bars155 agomir (RIBO, China) in Entranster™-in vivo Transfection Reagent
(Engreen, Beijing, China) at a dose of 1000 nmol/kg body weight
24 h before APAP administration. All mice were euthanized 24 h
after APAP administration. Blood samples were drawn and centri-
fuged. Liver tissues were harvested, and ﬁxed with 4% paraformalde-
hyde (PFA) for 24 h to 48 h until processed for routine histological
analysis, or snap-frozen in liquid nitrogen and stored at −80 °C for
further analysis.
2.3. Plasma ALT and AST measurements
Plasmawas collected by centrifuging blood samples at 2000 rpm for
10 min at 4 °C. Plasma alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) activity were measured using ALT and AST
commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing,
China), according to the manufacturer's instructions.
2.4. RNA extraction, cDNA synthesis, and quantitative real-time PCR
Total RNA was extracted from the liver tissue using TRIzol reagent
(Invitrogen, Carlsbad, CA). The expression of miR-155 was quantiﬁed
using a TaqMan miRNA assay kit (Life Technologies, Gaithersburg,
MD). Sno202, a reference small nuclear RNA, was used as the internal
control. RNA was converted to cDNA with the PrimeScript RT Reagent
Kit (Takara Bio, Otsu, Japan). To determine the mRNAs expression
level, quantitative real-time PCR were performed using a SYBR Premix
Ex Taq RT–PCR kit (Takara Bio, Otsu, Japan) for 40 cycles withiR-155 in liver and blood from APAP and PBS-treated mice. (B) H&E-staining of parafﬁn
lasma levels of AST and ALT from miR-155−/− and WT mice after APAP treatment. N =
represent the means ± SEM. *P b 0.05.
Fig. 3. Enhanced expressions of APAP-induced proinﬂammatory cytokine production in miR-155−/−mice. miR-155−/− and C57BL/6J WT mice were i.p. injected 300 mg/kg APAP or
PBS. 24 h later, the mice were sacriﬁced. Total RNAs of liver tissues were extracted. The mRNA levels of pro-inﬂammatory genes (CCL-2, TNFα, IL-1β, IL-6) in liver tissues were
measured by real time q-PCR. 155−/−: miR-155−/− mice. N = 5–6 mice per group. Data shown were representative of three independent experiments. Bars represent the
means ± SEM. *P b 0.05, **P b 0.01, ***P b 0.001.
Fig. 2. Enhanced APAP-induced liver cell death and neutrophil inﬁltration by miR-155 deﬁciency. Wild type mice and miR-155 mice received intraperitoneal injection of PBS and APAP,
respectively. 24 h later,micewere sacriﬁced and liver tissueswere harvested. (A) Cell apoptosiswasmeasured by TUNEL staining. (B) Immunostaining ofMPO inparafﬁn sections of APAP-
treated miR-155−/− and WT livers. Magniﬁcation: 200×. N = 5–6 mice per group.
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Fig. 4.Abnormally activatedNF-kappa-B signaling pathway inAPAP-treatedmiR-155−/−mice. (A) Theprotein levels of I-kappa-B-alpha, phosphorylated (Ser) I-kappa-B-alpha, p65, and
phosphorylated (Ser) p65in liver tissues fromAPAP-treatedWTandmiR-155−/−mice.β-Tubulinwas used to conﬁrm the equal protein loading. (B)mRNA and (C) protein levels of IKKε
in livers from APAP-treatedmiR-155−/− andWTmice, as determined by qPCR and western blotting. Data shownwere representative of three independent experiments. Bars represent
the means ± SEM. ***P b 0.001.
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mRNAwere normalized to GAPDHmRNA, shown as relative quantities.
Real-time PCR primers were as follows: CCL-2, forward 5′-
CATCCACGTGTTGGCTCA-3′ and reverse 5′-GATCATCTTGCTGGTGAAT
GAGT-3′; interleukin-6 (IL-6), forward 5′-TAGTCCTTCCTACCCCAA
TTTCC-3′ and reverse 5′-TTGGTCCTTAGCCACTCCTTC-3′; tumor necrosis
factor α (TNFα), forward 5′-AAACACAAGATGCTGGGACA-3′ and re-
verse 5′-TTGATGGTGGTGCATGAGAG-3′; interleukin-1β (IL-1β), for-
ward 5′-GCACTACAGGCTCCGAGATG-3′ and reverse 5′-CGTTGCTTG
GTTCTCCTTGTAC-3′; GAPDH, forward 5′-CAGAACATCATCCCTGCATC-
3′ and reverse 5′-CTGCTTCACCACCTTCTTGA-3′; IKKε, forward 5′-ACC
ACTAACTACCTGTGGCAT-3′ and reverse 5′-CCTCCCCGGATTTCTTG
TTTC-3′; Jun., forward 5′-ATCCACGGCCAACATGCTC-3′ and reverse 5′-
ACGTTTGCAACTGCTGCGTTAG-3′; Fos, forward 5′-TTACGCCAGAGCGG
GAATG-3′ and reverse 5′-GTTCCCTTCGGATTCTCCGTTT-3′; Chop, for-
ward 5′-AGCTGGAAGCCTGGTATGAGGA-3′ and reverse 5′-AGCTA
GGGACGCAGGGTCAA-3′; Bim forward 5′-CCGGAGATACGGATTG
CACAG-3′ and reverse 5′-CAGCCTCGCGGTAATCATTTG-3′.Fig. 5. Identiﬁcation of IKKε as a direct target of miR-155. (A) The binding sites of miR-155
(psiCheck2), or a construct encoding IKKε3′-UTR, combined the miR-155 mimic (B, left) or mi
shown were representative of three independent experiments. Bars represent the means ± SE2.5. Western blotting
The liver tissues were lysed by RIPA buffer (Thermo Scientiﬁc, Rock-
ford, IL). Protein amountweremeasured by the BCA-kit (Thermo Scien-
tiﬁc, Rockford, IL) and then normalized before all western blot
experiments. Lysate proteins were separated by SDS-PAGE, transferred
to PVDF membranes, and probed with primary antibodies directed
against phosphorylated (Ser) p65, p65, phosphorylated (Ser) I-kappa-
B-alpha, I-kappa-B-alpha, IKKε (Cell Signaling), β-tubulin (Abcam). All
results were normalized to loading controls.
2.6. Luciferase assay
For the 3′-UTR reporter assay, the psiCHECK-2 vector (Promega,
Madison, WI) was used to clone the 3′-UTR of IKKε. Primers used
were as follows: IKKε3’ UTR, 5′-CCGCTCGAGCACTCAGAAGCAATAGA
AAC-3′ (forward) and 5′-ATAAGAATGCGGCCGCGTATTTATTCCATGT
CTGAAG-3′ (reverse). miR-155 mimics, negative controls (NC) andin IKKε. (B) The luciferase assay. 293T cells were transfected with the control construct
R-155 inhibitor (B, right). After 24 h, luciferase activity in cells lysates was detected. Data
M. *P b 0.05, ***P b 0.001, NS, not signiﬁcant.
343K. Yuan et al. / International Immunopharmacology 40 (2016) 339–346inhibitor were purchased from GenePharma (Shanghai, China).293T
cells were cultured in 96-well plates and were transfected with a mix-
ture of 5 ng of 3′UTR luciferase reporter vector or empty vector together
with miR-155 mimics, NC mimics or miR-155 inhibitor by lipofecta-
mine2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. The cells were rinsed and then harvested 24 h after trans-
fection. Cell lysate were subjected to luciferase activity assay. The ratio
of Renilla luciferase activity to ﬁreﬂy luciferase activity was calculated.
2.7. Histology analysis
Parafﬁn embedded sections (5 μm thick) fromﬁxed liver tissuewere
stained with hematoxylin and eosin (H&E) routinely for conventional
morphological evaluation. Anti-MPO (Abcam, Cambridge, UK) antibody
was used for analysis of MPO-positive cells (neutrophils). In order to
evaluate liver cell death, terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assaywas performed by using the ApopTag®
Peroxidase In Situ Apoptosis Detection Kit (Merck Millipore, Billerica,
MA, USA). Photomicrographswere taken using an Olympus uprightmi-
croscope (Olympus, Tokyo, Japan).Fig. 6. Efﬁcacy ofmiR-155 agomir in preventingAPAP-induced liver injury. (A) Design of the pre
a dose of 1000 nmol/kg body weight 24 h before APAP administration. After 24 h, liver and b
staining of liver tissues of miR-155 agomir or NC treated mice. Scale bar: 10 μm. (D) The plas
three independent experiments. Bars represent the means ± SEM. *P b 0.05, ***P b 0.001.2.8. Statistical analysis
Data organization was performed using GraphPad Prism 6 soft-
ware (La Jolla, CA). Differences between groups were analyzed for
statistical signiﬁcance with unpaired t-test. At least three indepen-
dent experiments were performed to conﬁrm the reproducibility of
each experiment. All data was shown as the means ± standard
error of the mean (SEM). A P value b0.05 was deemed statistically
signiﬁcant.
3. Results
3.1. Aggravated liver damage induced by APAP in miR-155−/−mice
In an attempt to study the role of miR-155 in APAP-induced liver
toxicity, we ﬁrst analyzed the expression of miR-155 in this process.
miR-155 expression was signiﬁcantly increased in liver 24 h post
APAP injection. The levels of miR-155 in bloodwere also elevated, com-
paredwith PBS treated group (Fig. 1A). To further investigate the role of
miR-155 in APAP-induced liver damage, we analyzed the toxic effect ofvention study.Micewere injected (i.v.) negative control (NC) agomir ormiR-155 agomir at
lood samples were harvested. (B) The expression of miR-155 in the liver tissues (C) H&E
ma levels of AST and ALT. N = 5–6 mice per group. Data shown were representative of
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155−/− mice showed markedly aggressive live damage compared
with WT mice, as assayed by histopathology (Fig. 1B). The serum levels
of the two hepatic enzymes AST and ALT that are widely recognized as
indicators of hepatic injury were signiﬁcantly increased in miR-
155−/−mice relative to WT mice (Fig. 1C).
It is reported that APAP treatment induced a mass of cell death in
livers [22]. We noted that miR-155−/−mice showed more apoptosis
compared with WT groups in response to APAP, as measured by
TUNEL assay (Fig. 2A). However, miR-155 deﬁciency itself had no effect
on liver cell death (Fig. S1). In linewith that, the expressions of some cell
death related genes, such as Jun, Fos, Chop, and Bim were signiﬁcantly
increased in miR-155 deﬁcient mice (Fig. S2).
Therefore, taken together, we demonstrated that miR-155 is highly
induced in liver and blood after APAP treatment and deletion of miR-
155 aggravates APAP induced liver damage.
3.2. Enhanced inﬂammation in APAP-treated miR-155−/−mice
Recently, accumulating evidence has demonstrated that neutrophils
are involved in the pathogenesis of the acute liver injury [23]. After
APAP treatment, a large number of neutrophils were accumulated in
the inﬂamed livers, as measured by MPO IHC staining (Fig. 2B). Loss of
miR-155 did not enhance neutrophil accumulation in liver (Fig. S3A).
However, in the context of APAP treatment, miR-155 deﬁciency aug-
mented the neutrophil inﬁltration (Fig. 2B, Fig. S3B). The inﬂammatory
factors, such as TNFα and IL-6 that are secreted by both innate immune
cells and endothelial cells play critical roles in APAP-induced liver injury
[24,25]. Thus, we next analyzed the effect of miR-155 on the inﬂamma-
tion related genes expression. Consistentwith other studies, the expres-
sions of TNFα, IL-1β, CCL-2 and IL-6 were highly induced after APAP
treatment (Fig. 3). However, miR-155 deﬁciency remarkably augment-
ed these genes expression. Therefore, these data indicated that loss of
miR-155worsens the liver damage via promoting various inﬂammatory
cytokines expression.
3.3. Aberrantly activated NF-kappa-B signaling in APAP-treated miR-
155−/−mice
NF-kappa-B signaling is well known to play a crucial role in inﬂam-
mation [26]. To further study howmiR-155 promotes the expression ofFig. 7. Decreased APAP-induced liver cell death and neutrophil inﬁltration by miR-155 overex
respectively. 24 h later, the mice received intraperitoneal injection of APAP. After 24 h, the m
TUNEL staining. (B) Immunostaining of MPO in parafﬁn sections of APAP-treated miR-155−
N= 5–6 mice per group.inﬂammatorymediators, we tested the activation of NF-kappa-B signal-
ing. The total protein levels of p65were dramatically elevated in the ab-
sence of miR-155. Moreover, the phosphorylation levels of p65was also
enhanced in miR-155 deﬁcient mice related toWT controls (Fig. 4A). In
a rest state, NF-kappa-B is sequestered in cytoplasm by I-kappa-B. Upon
activation, I-kappa-B is phosphorylated by I-kappa-B kinase, leading to
NF-kappa-B dissociation and nuclear translocation, which then initiates
the transcription of various NF-kappa-B downstream genes [26]. We
found that loss of miR-155 markedly increased the expression of IKKε,
at both RNA (Fig. 4B) and protein levels (Fig. 4C). Consequently, the
phosphorylation levels of I-kappa-B were elevated in the absence of
miR-155 (Fig. 4A). Therefore, our data indicated that miR-155 prevents
inﬂammatory cytokine expression via negatively regulating multiple
key components in NF-kappa-B signaling pathway.
3.4. Identiﬁcation of IKKε as a direct target of miR-155
It is known thatmiRNA regulates gene expression by base-pairing its
targetmRNAswith the “seeding sequence”, resulting inmRNAdegrada-
tion or translation repression [27]. Recent work revealed that miR-155
inhibits endothelial inﬂammation via targeting p65 [28]. In line with
that, we noted that the protein levels of p65 were notably elevated by
the loss of miR-155 (Fig. 4A). Moreover, the expression of IKKε was
also increased in miR-155 deﬁcient mice (Fig. 4B, C). However, little is
known about the target effect ofmiR-155 on IKKε in liver inﬂammation.
Sequence alignment revealed that the 3′UTR of IKKε contains the bind-
ing site ofmiR-155 seed sequence (Fig. 5A). To prove the target relation-
ship, we cloned IKKε 3′UTR in psiCHECK2 vector and co-transfected it
with miR-155 mimic or inhibitors and their corresponding negative
controls in Hela cell, respectively. We found that miR-155 regulated lu-
ciferase activity in an IKKε 3′UTR dependent manner (Fig. 5B, C). Thus,
these data demonstrated that the IKKε is a direct target of miR-155.
3.5. Attenuated liver damage by in vivo administration of miR-155 agomir
In the aforementioned data, we showed that miR-155 expression
was signiﬁcantly increased after APAP treatment, and knockout of
miR-155 worsened liver damage via promoting various inﬂammatory
cytokine production. We next want to ask whether in vivo overexpres-
sion of miR-155 could prevent the APAP-induced liver inﬂammation.pression. Wild type mice were treated with miR-155 agomir or agomir negative control,
ice were sacriﬁced and liver tissues were harvested. (A) Cell apoptosis was measured by
/− and WT livers. Magniﬁcation: 200×. N = 5–6 mice per group. Magniﬁcation: 200×.
Fig. 8. Inhibited downstream activation of NF-kappa-B signaling by miR-155 overexpression. (A) Protein levels of I-kappa-B-alpha, phosphorylated (Ser) I-kappa-B-alpha, p65,
phosphorylated (Ser) p65, and IKKεin liver tissues from APAP-treated mice intravenously injected with NC agomir or miR-155 agomir. β-Tubulin was used to conﬁrm equal protein
loading. (B) mRNA levels of IKKεin livers from APAP-treated mice intravenously injected with NC agomir or miR-155 agomir, as determined by qPCR. Data shown were representative
of three independent experiments. Bars represent the means ± SEM. *P b 0.05.
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utilized to mimic miR-155 function in vivo (Fig. 6A). Systemic adminis-
tration of miR-155 agomir dramatically elevated the levels of miR-155
in liver (Fig. 6B). As expected, mice treated with miR-155 agomir
showed less hepatic lesions, compared with those treated with the
agomir negative control (NC) (Fig. 6C). Consistent with these data, the
circulating levels of AST and ALT were signiﬁcantly decreased in miR-Fig. 9. Effects of miR-155 agomir on proinﬂammatory cytokine expression in liver tissues
from APAP-treatedmice. mRNA levels of pro-inﬂammatory genes (CCL-2, TNFα, IL-1B, IL-
6) in liver tissues in APAP-treated mice injected with miR-155 agomir or NC agomir. N =
5–6 mice per group. Data shown were representative of three independent experiments.
Bars represent the means ± SEM. *P b 0.05.155 agomir treated mice relative to the NC group (Fig. 6D). Moreover,
overexpression of miR-155 attenuated cell death (Fig. 7A) and neutro-
phil inﬁltration in livers (Fig. 7B, Fig. S3B). Furthermore, we noted that
the expression of the two key components of NF-kappa-B signaling,
p65 and IKKε, were markedly reduced after miR-155 agomir treatment
(Fig. 8). Accordingly, the downstream genes of NF-kappa-B signaling,
such asIL-6 and TNFα were signiﬁcantly down-regulated in miR-155
agomir treated livers (Fig. 9).
4. Discussion
Overdose of APAP can cause the acute hepatocellular necrosis, fol-
lowing the activation of multiple innate immune cells that secrete a
wide variety of cytokines and chemokines, resulting in the severe in-
ﬂammatory response in liver. In this manuscript, we revealed a protec-
tive role of miR-155 in APAP-induced liver inﬂammation. In APAP-
treated liver, miR-155 is highly induced, which negatively regulates
p65 and IKKε expression, leading to the reduced activation of NF-
kappa-B signaling.
miR-155 is awell-knownmicroRNA thatmediates the inﬂammatory
responses via regulating the expression of various target genes. Zhou et
al. revealed thatmiR-155promotes pristane induced acute lung damage
via targeting BCL-6, SOCS1, and PPARα, which are the negative regula-
tors of NF-kappa-B signaling [29]. Recently, Bala et al. demonstrated
that deletion of miR-155 protects the mice against alcohol induced
liver steatosis and inﬂammation [21]. In contrast, Wu et al. revealed
that TNFα-induced miR-155 acts as a negative feedback mediator of
NF-kappa-B signaling by directly regulating p-65 expression in endo-
thelial cells [28]. In another experimentation, Lu et al. reported that Ep-
stein-Barr Virus inducedmiR-155 alleviates the activation of NF-kappa-
B signaling through downregulating IKKɛ expression [30]. Using miR-
155−/− mice and miR-155 in vivo administration, we revealed an
anti-inﬂammatory role of miR-155 in APAP induced liver injury. The
discrepancy between pro-inﬂammatory and anti-inﬂammatory roles
of miR-155, we think, might be explained by the fact that different
mouse and cell models are used for evaluating the functions ofmiR-155.
miRNAs mediate diverse biological processes by reinforcing tran-
scriptional programs and attenuating aberrant mRNA expression. In-
creasing evidence has shown that deregulated miRNAs are involved in
the pathogenesis of various human diseases [31–33]. Importantly,
some disease-related miRNAs can be detected in biological ﬂuids, such
as serum [34] and urine [35], allowing the less-invasive monitoring. Re-
cently, several lines of experimentation revealed that the serum levels
of miR-155 are highly increased in drug-induced liver diseases, includ-
ing APAP [36,37]. In line with these studies, we noted that miR-155
346 K. Yuan et al. / International Immunopharmacology 40 (2016) 339–346was upregulated in blood after APAP treatment. Moreover, in vivo ad-
ministration of miR-155 agomir dramatically increased the circulating
levels ofmiR-155 (data not shown), which alleviates liver injury and in-
ﬂammation. Therefore, we proposed that the blood levels of miR-155
might be used as a prognostic biomarker for APAP-induced liver dam-
age in clinic.
miRNAs are frequently deregulated in various human diseases, sug-
gesting that they might serve as potential pharmaceutic targets for de-
velopment of miRNA-based therapeutics [31,38–41]. In a recent phase
2 study, Janssen et al. demonstrated that silencing miR-122 via
miravirsen, a chemically modiﬁed oligonucleotide, reduces HCV RNA
levels in patients with chronic HCV infection [42]. Here, we revealed
that in vivo administration of miR-155 agomir inhibits liver damage
and inﬂammation, implying the signiﬁcance of using miR-155 agonist
in treatment for the liver disease induced by APAP overdose in clinic.
Therefore, taken together, our data demonstrated that miR-155 in-
hibits APAP-induced aberrant activation of NF-kappa-B signaling via
regulating p65 and IKKε expression. In vivo overexpression of miR-
155 attenuates APAP-induced liver damage and inﬂammation. These
ﬁndings provide a promising therapeutic strategy for treatment of
APAP overdose-induced liver damage using miR-155 agonist.
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